01 / DESIGN
What was studied?
A prespecified analysis grouped FLOW participants with diabetes and chronic kidney disease by their baseline kidney function.
02 / FINDINGS
What did the researchers report?
Serious adverse events were less frequent with semaglutide across the reported groups. Gastrointestinal events leading to discontinuation remained more frequent than with placebo.
03 / LIMITS
How should it be interpreted?
Safety collection was selective and this analysis was descriptive. It does not establish safety outside the trial population or turn fewer serious events into an absence of adverse effects.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.